ESTRO 2025 - Abstract Book

S631

Clinical - Breast

ESTRO 2025

hyperpigmentation, telangiectasia, pruritus, pain, fibrosis and asthenia were similar (p > 0.05). No >G3 toxicity was recorded. Additionally, no neuropathies or plexopathies were observed post-radiotherapy, either acutely or chronically. In a sub-analysis according to the different nodal areas treated, no differences were observed either. Respecting cosmesis, there were no significant differences between groups (p > 0.05), with patients presenting not less than good cosmesis. Conclusion: The irradiation of the nodal areas with the Fast-forward scheme (26 Gy/5.2 Gy/5 sessions) seems to be a safe procedure, allowing a good control of the disease without increasing adverse effects or toxicity. This could benefit patients by reducing treatment time and thereby improving their quality of life.

Keywords: FAST-Forward nodal irradiation

References: Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet . 2020;395(10237):1613-1626. doi:10.1016/S0140-6736(20)30932-6

4550

Digital Poster Financial toxicity in breast cancer patients treated with radiation therapy - a cross-sectional study Monica E Chirila 1,2 , Renata Zahu 1,3 , Tiberiu Popescu 1 , Alexandru Iacob 1 , Claudiu Hopirtean 1 , Bunta Ovidiu 4 , Mihai Zerbea 4 , Andreea Marita 5 , Adelina Brezae 5 , Dorin Ordean 5 , Gabriel Kacso 1,3 1 Department of Radiation Oncology, Amethyst Radiotherapy Centre, Cluj-Napoca, Romania. 2 Department of Clinical Development, MVision AI, Helsinki, Finland. 3 Department of Medical and Radiation Oncology, University of Medicine and Pharmacy “Iuliu Hațieganu”, Cluj-Napoca, Romania. 4 Department of Radiation Oncology, Amethyst Radiotherapy Centre, Timișoara, Romania. 5 Department of Radiation Oncology, Amethyst Radiotherapy Centre, Alba-Iulia, Romania Purpose/Objective: Cancer patients benefit from publicly reimbursed investigations and treatments. However, there are additional costs that are not covered by insurance. This study aimed to assess the out-of-pocket expenses of breast cancer patients. Material/Methods: An online questionnaire was sent to female breast cancer patients who completed radiotherapy with curative intent in Amethyst Radiotherapy Centers in Cluj, Alba, and Timișoara between August 2023 and November 2024. Results: We received answers from 110 participants with a median age of 53 years (35-82). The majority (N=91; 82.7%) lived in urban areas, had an education level of at least high school (N=102; 92.7%), were married (N=80; 72.7%), and had Romanian ethnicity (N=101; 91.8%). Most of the respondents were employed at diagnosis (N=76; 69.1%), had public insurance only (N=104; 94.5%), and had a monthly income below the average country value (less than 1000 euros) (N=77; 70%). All patients received radiation therapy as part of their multidisciplinary treatment, and almost all received surgery (N=108; 98.2%). Intravenous and oral treatments were mentioned by 65 (59.1%) and 80 (72.7%) patients. Total out-of-pocket expenses of more than 400 euros for each of the following categories (investigations, transport, accommodation, and side effects’ treatment) were mentioned by 71 (64.5%), 56 (50.9%), 34 (30.9%), and 10 (9.1%) participants, respectively. Many of the patients working before diagnosis (N=76) returned full-time (N=30, 39.5%), and almost one-third permanently ceased the previous activity (N=22; 28.9%). One-quarter searched for